Search
Bufexamac
go.drugbank.com/drugs/DB13346ApprovedWithdrawnBufexamac was also withdrawn by the EMA in April 2010. … It is typically administered topically for the treatment of subacute and chronic eczema of the skin, including atopic eczema and other inflammatory dermatoses, as well as sunburn and other minor burns,
Metocurine iodide
go.drugbank.com/drugs/DB00416ApprovedWithdrawnrelease and has some ganglion blocking activity. … It is used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy Metocurine iodide has a moderate risk of inducing histamine
Setmelanotide
go.drugbank.com/drugs/DB11700ApprovedInvestigational[A224449] Imcivree was granted EMA orphan designation on November 19, 2018 [L24559] and FDA approval on November 25, 2020.[L24429] On May 4, 2023, it was approved by Health Canada.[L46327] … [A224449] Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate.
Fluoride ion F-18
go.drugbank.com/drugs/DB09398ApprovedInvestigationalIncreased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa
Certolizumab pegol
go.drugbank.com/drugs/DB08904ApprovedInvestigationalThe absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. … done directly in bacterial hosts such as _E. coli_.
Products: CIMZIA 200MG, CIMZIA 200MG FERRevefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigationalThe LAMA group falls into a parent category known as long-acting inhaled bronchodilators and this type of agents are recommended as a maintenance therapy for chronic obstructive pulmonary disease (COPD … [A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Isoflavone
go.drugbank.com/drugs/DB12007ApprovedInvestigationalWithdrawnIsoflavone is found as one of constituents in oral over-the-counter dietary supplements indicated for improved bone mass density and body fat regulation. … Isoflavone is a soy phytoestrogen and a biologically active component of several agriculturally important legumes such as soy, peanut, green peas, chick peas and alfalfa [A33103].
Aminobenzoic acid
go.drugbank.com/drugs/DB02362ApprovedWithdrawnA member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
Mixtures: Multi B Complex Plus 500mg Vitamin C TabletsUblituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012. … [L44508] The next year, June 2023, ublituximab was also approved by the EMA for the treatment of relapsing forms of multiple sclerosis in adult patients.[L47486]
Fluticasone
go.drugbank.com/drugs/DB13867ApprovedInvestigationalWithdrawn[DB00588] was first approved in 1990[L5962] and [DB08906] was approved in 2007[L5965]. … Fluticasone is a synthetic glucocorticoid available as 2 esters, [DB08906] and [DB00588][F4355,F4358,F4361,F4364][FDA Label].